Home / Market News / $PACB
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Barclays Maintains Underweight Rating on PacBio, Raises Price Target

Nov 6, 2026, 2:09 PM UTC · Primary ticker $PACB

Barclays maintained an 'Underweight' rating on PacBio but increased its price target by 60% from $1.25 to $2.00. Despite the price target increase, it still suggests a potential downside from the stock's previous closing price, indicating a mixed signal for investors.

Barclays maintained its 'Underweight' rating on Pacific Biosciences of California, Inc. (PacBio), signaling continued caution about the stock's prospects. However, the firm simultaneously raised its price target from $1.25 to $2.00, a significant 60% increase. This adjustment is notable because it suggests a revised, albeit still negative, outlook on the company's valuation. While the price target increase might seem positive, it still implies a potential downside from the previous closing price of $2.55, indicating that Barclays believes the stock is currently overvalued. For traders, this presents a nuanced situation: a higher price target could be seen as a less bearish stance, but the maintained 'Underweight' rating and implied downside suggest continued pressure on the stock in the short to medium term. The key risk is that the market may interpret the maintained 'Underweight' rating more strongly than the price target increase, leading to further selling pressure.

$PACB negative Underweight rating maintained, price target still implies downside
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.